The relationship between fibromyalgia and major depressive disorder: A comprehensive review

Current Medical Research and Opinion

Volumn 24, Issue 8, 2008, Pages 2359-2371

  Pae, Chi Un ^a,b   Luyten, Patrick ^c   Marks, David M ^b   Han, Changsu ^b,d   Park, Sung Hwan ^a   Patkar, Ashwin A ^b   Masand, Prakash S ^b   van Houdenhove, Boudewijn ^e  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Korea University   (South Korea)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Antidepressant; Fibromyalgia; Major depressive disorder; Relationship

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CYCLOBENZAPRINE; DOSULEPIN; DULOXETINE; ESTROGEN; FLUOXETINE; GROWTH HORMONE; MAPROTILINE; MILNACIPRAN; PAROXETINE; PLACEBO; PREGABALIN; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P; TRICYCLIC ANTIDEPRESSANT AGENT;

ANALGESIC ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; ESTROGEN BLOOD LEVEL; EVIDENCE BASED MEDICINE; FAMILY HISTORY; FIBROMYALGIA; GENETIC POLYMORPHISM; HUMAN; MAJOR DEPRESSION; MEDLINE; MONOTHERAPY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SEROTONIN UPTAKE; THYROID DISEASE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FIBROMYALGIA; HUMANS;

EID: 50149090660     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802288338     Document Type: Review

References (144)

1. Ackenheil M. Genetics and pathophysiology of affective disorders: relationship to fibromyalgia. Z Rheumatol 1998; 57(Suppl 2):5-7
2. Offenbaecher M, Glatzeder K, Ackenheil M. Self-reported depression, familial history of depression and fibromyalgia (FM), and psychological distress in patients with FM. Z Rheumatol 1998;57(Suppl 2):94-6
3. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
4. Ratcliffe GE, Enns MW, Belik SL. Chronic pain conditions and suicidal ideation and suicide attempts: an epidemiologic perspective. Clin J Pain 2008;24:204-10
5. Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. Arthritis Rheum 2004;50:944-52
6. Arnold LM, Hudson JI, Keck PE, et al. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 2006;67: 1219-25
7. Burckhardt CS, O'Reilly CA, Wiens AN, et al. Assessing depression in fibromyalgia patients. Arthritis Care Res 1994;7:35-9
8. Sayar K, Gulec H, Topbas M. Alexithymia and anger in patients with fibromyalgia. Clin Rheumatol 2004;23:441-8
9. McBeth J, Macfarlane GJ, Benjamin S, et al. The association between tender points, psychological distress, and adverse childhood experiences: a community-based study. Arthritis Rheum 1999;42:1397-404
10. Kivimaki M, Leino-Arjas P, Virtanen M, et al. Work stress and incidence of newly diagnosed fibromyalgia: prospective cohort study. J Psychosom Res 2004;57:417-22
11. Landro NI, Stiles TC, Sletvold H. Memory functioning in patients with primary fibromyalgia and major depression and healthy controls. J Psychosom Res 1997;42:297-306
12. Martinez-Lavin M. Biology and therapy of fibromyalgia. Stress, the stress response system, and fibromyalgia. Arthritis Res Ther 2007;9:216
13. Pamuk ON, Yesil Y, Cakir N. Factors that affect the number of tender points in fibromyalgia and chronic widespread pain patients who did not meet the ACR 1990 criteria for fibromyalgia: are tender points a reflection of neuropathic pain? Semin Arthritis Rheum 2006;36:130-4
14. Lundberg G, Gerdle B. Tender point scores and their relations to signs of mobility, symptoms, and disability in female home care personnel and the prevalence of fibromyalgia syndrome. J Rheumatol 2002;29:603-13
15. Staud R, Vierck CJ, Cannon RL, et al. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001;91:165-75
16. Anderberg UM, Liu Z, Berglund L, et al. Plasma levels on nociceptin in female fibromyalgia syndrome patients. Z Rheumatol 1998;57(Suppl 2):77-80
17. Blanco LE, de Serres FJ, Fernandez-Bustillo E, et al. Alpha1-Antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. Med Hypotheses 2005;64:759-69
18. Wood PB, Patterson JC, 2nd, Sunderland JJ, et al. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain 2007;8:51-8
19. Goodnick PJ, Sandoval R. Psychotropic treatment of chronic fatigue syndrome and related disorders. J Clin Psychiatry 1993;54:13-20
20. Crofford LJ. The hypothalamic-pituitary-adrenal stress axis in fibromyalgia and chronic fatigue syndrome. Z Rheumatol 1998;57(Suppl 2):67-71
21. Martinez-Lavin M, Hermosillo AG. Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin Arthritis Rheum 2000;29:197-9
22. Wolfe F, Hawley DJ. Psychosocial factors and the fibromyalgia syndrome. Z Rheumatol 1998;57(Suppl 2):88-91
23. Raphael KG, Janal MN, Nayak S, et al. Familial aggregation of depression in fibromyalgia: a community-based test of alternate hypotheses. Pain 2004;110:449-60
24. Hudson JI, Pope HG, Jr. The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin North Am 1996;22:285-303
25. Kanaan RA, Lepine JP, Wessely SC. The association or otherwise of the functional somatic syndromes. Psychosom Med 2007;69:855-9
26. Leiknes KA, Finset A, Moum T, et al. Current somatoform disorders in Norway: prevalence, risk factors and comorbidity with anxiety, depression and musculoskeletal disorders. Soc Psychiatry Psychiatr Epidemiol 2007;42:698-710
27. Aggarwal VR, McBeth J, Zakrzewska JM, et al. The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors? Int J Epidemiol 2006;35:468-76
28. Haug TY, Mykletun A, Dahl AA. The association between anxiety, depression, and somatic symptoms in a large population: the HUNT-II study. Psychosom Med 2004;66:845-51
29. Kurland JE, Coyle WJ, Winkler A, et al. Prevalence of irritable bowel syndrome and depression in fibromyalgia. Dig Dis Sci 2006;51:454-60
30. Ercolani M, Trombini G, Chattat R, et al. Fibromyalgic syndrome: depression and abnormal illness behavior. Multicenter investigation. Psychother Psychosom 1994;61:178-86
31. Guven AZ, Kul Panza E, Gunduz OH. Depression and psychosocial factors in Turkish women with fibromyalgia syndrome. Eura Medicophys 2005;41:309-13
32. Hudson JI, Hudson MS, Pliner LF, et al. Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. Am J Psychiatry 1985;142:441-6
33. Kirmayer LJ, Robbins JM, Kapusta MA. Somatization and depression in fibromyalgia syndrome. Am J Psychiatry 1988; 145:950-4
34. Walker EA, Keegan D, Gardner G, et al. Psychosocial factors in fibromyalgia compared with rheumatoid arthritis: I. Psychiatric diagnoses and functional disability. Psychosom Med 1997; 59:565-71
35. Ahles TA, Khan SA, Yunus MB, et al. Psychiatric status of patients with primary fibromyalgia, patients with rheumatoid arthritis, and subjects without pain: a blind comparison of DSM-III diagnoses. Am J Psychiatry 1991;148:1721-6
36. Malt EA, Berle JE, Olafsson S, et al. Fibromyalgia is associated with panic disorder and functional dyspepsia with mood disorders. A study of women with random sample population controls. J Psychosom Res 2000;49:285-9
37. Bondy B, Spaeth M, Offenbaecher M, et al. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 1999;6:433-9
38. Buskila D, Cohen H, Neumann L, et al. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 2004;9:730-1
39. Gursoy S, Erdal E, Herken H, et al. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 2003;23:104-7
40. Kang RH, Choi MJ, Paik JW, et al. Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. Int J Psychiatr Med 2007;37:315-29
41. Frokjaer VG, Mortensen EL, Nielsen FA, et al. Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry 2008;63:569-76
42. Shaikh SA, Strauss J, King N, et al. Association study of serotonin system genes in childhood-onset mood disorder. Psychiatr Genet 2008;18:47-52
43. Offenbaecher M, Bondy B, de Jonge S, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999;42:2482-8
44. Serretti A, Kato M, De Ronchi D, et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007;12:247-57
45. Cohen H, Buskila D, Neumann L, et al. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum 2002; 46:845-7
46. Gursoy S. Absence of association of the serotonin transporter gene polymorphism with the mentally healthy subset of fibromyalgia patients. Clin Rheumatol 2002;21:194-7
47. Van Houdenhove B, Luyten P. Stress, depression and fibromyalgia. Acta Neurol Belg 2006;106:149-56
48. Crofford LJ. Violence, stress, and somatic syndromes. Trauma Violence Abuse 2007;8:299-313
49. Shelton RC. The molecular neurobiology of depression. Psychiatr Clin North Am 2007;30:1-11
50. Moldofsky H. Rheumatic pain modulation syndrome: the interrelationships between sleep, central nervous system serotonin, and pain. Adv Neurol 1982;33:51-7
51. Russell IJ, Michalek JE, Vipraio GA, et al. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992;19:104-9
52. Maes M, Verkerk R, Delmeire L, et al. Serotonergic markers and lowered plasma branched-chain-amino acid concentrations in fibromyalgia. Psychiatry Res 2000;97:11-20
53. Bazzichi L, Giannaccini G, Betti L, et al. Alteration of serotonin transporter density and activity in fibromyalgia. Arthritis Res Ther 2006;8:99
54. Stratz T, Samborski W, Hrycaj P, et al. [Serotonin concentration in serum of patients with generalized tendomyopathy (fibromyalgia) and chronic polyarthritis]. Med Klin (Munich) 1993; 88:458-62
55. Legangneux E, Mora JJ, Spreux-Varoquaux O, et al. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology (Oxford) 2001;40:290-6
56. Russell IJ, Vaeroy H, Javors M, et al. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-6
57. Field T, Diego M, Cullen C, et al. Fibromyalgia pain and substance P decrease and sleep improves after massage therapy. J Clin Rheumatol 2002;8:72-6
58. Hamaty D, Valentine JL, Howard R, et al. The plasma endorphin, prostaglandin and catecholamine profile of patients with fibrositis treated with cyclobenzaprine and placebo: a 5-month study. J Rheumatol Suppl 1989;19:164-8
59. Larson AA, Giovengo SL, Russell IJ, et al. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000;87:201-11
60. Blier P, Gobbi G, Haddjeri N, et al. Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J Psychiatry Neurosci 2004;29:208-18
61. Staud R, Spaeth M. Psychophysical and neurochemical abnormalities of pain processing in fibromyalgia. CNS Spectr 2008;13 (3 Suppl 5):12-17
62. Lesch KP, Laux G, Pfuller H, et al. Growth hormone (GH) response to GH-releasing hormone in depression. J Clin Endocrinol Metab 1987;65:1278-81
63. Bennett RM. Disordered growth hormone secretion in fibromyalgia: a review of recent findings and a hypothesized etiology. Z Rheumatol 1998;57(Suppl 2):72-6
64. Riedel W, Layka H, Neeck G. Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Z Rheumatol 1998;57(Suppl 2):81-7
65. Deuschle M, Blum WF, Strasburger CJ, et al. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 1997;22:493-503
66. Bethea CL, Gundlah C, Mirkes SJ. Ovarian steroid action in the serotonin neural system of macaques. Novartis Found Symp 2000;230:112-30; discussion 30-3
67. Halbreich U, Rojansky N, Palter S, et al. Estrogen augments serotonergic activity in postmenopausal women. Biol Psychiatry 1995;37:434-41
68. McCain GA, Tilbe KS. Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. J Rheumatol Suppl 1989;19:154-7
69. Neeck G, Riedel W. Thyroid function in patients with fibromyalgia syndrome. J Rheumatol 1992;19:1120-2
70. Neeck G. Pathogenic mechanisms of fibromyalgia. Ageing Res Rev 2002;1:243-55
71. Glass JM, Lyden AK, Petzke F, et al. The effect of brief exercise cessation on pain, fatigue, and mood symptom development in healthy, fit individuals. J Psychosom Res 2004;57:391-8
72. McBeth J, Silman AJ, Gupta A, et al. Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: findings of a population-based prospective cohort study. Arthritis Rheum 2007;56:360-71
73. Van Houdenhove B, Egle UT. Fibromyalgia: a stress disorder? Piecing the biopsychosocial puzzle together. Psychother Psychosom 2004;73:267-75
74. Adler GK, Geenen R. Hypothalamic-pituitary-adrenal and autonomic nervous system functioning in fibromyalgia. Rheum Dis Clin North Am 2005;31:187-202, xi
75. Antonijevic IA. Depressive disorders - is it time to endorse different pathophysiologies? Psychoneuroendocrinology 2006; 31:1-15
76. Anderberg UM, Marteinsdottir I, Theorell T, et al. The impact of life events in female patients with fibromyalgia and in female healthy controls. Eur Psychiatry 2000;15:295-301
77. Boisset-Pioro MH, Esdaile JM, Fitzcharles MA. Sexual and physical abuse in women with fibromyalgia syndrome. Arthritis Rheum 1995;38:235-41
78. Van Houdenhove B. Premorbid 'overactive' lifestyle and stress-related pain/fatigue syndromes. J Psychosom Res 2005; 58:389-90
79. Imbierowicz K, Egle UT. Childhood adversities in patients with fibromyalgia and somatoform pain disorder. Eur J Pain 2003; 7:113-19
80. Van Houdenhove B, Luyten P. Customizing treatment of chronic fatigue syndrome/fibromyalgia: the role of perpetuating factors. Psychosomatics. In Press
81. Bazzichi L, Rossi A, Massimetti G, et al. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 2007;25:225-30
82. Amital D, Fostick L, Polliack ML, et al. Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: are they different entities? J Psychosom Res 2006;61:663-9
83. Amir M, Kaplan Z, Neumann L, et al. Posttraumatic stress disorder, tenderness and fibromyalgia. J Psychosom Res 1997; 42:607-13
84. Sherman JJ, Turk DC, Okifuji A. Prevalence and impact of posttraumatic stress disorder-like symptoms on patients with fibromyalgia syndrome. Clin J Pain 2000;16:127-34
85. Theadom A, Cropley M, Humphrey KL. Exploring the role of sleep and coping in quality of life in fibromyalgia. J Psychosom Res 2007;62:145-51
86. Van Houdenhove B, Luyten P, Egle U. Stress as a key concept in chronic pain and fatigue disorders. J Musculoskeletal Pain. In Press
87. McLean SA, Williams DA, Harris RE, et al. Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum 2005;52:3660-9
88. Luyten P, Van Houdenhove B. Cortisol secretion and symptoms in patients with fibromyalgia: comment on the article by McLean et al. Arthritis Rheum 2006;54:2345-6; author reply 6-7
89. Luyten P, Blatt SJ. Looking back towards the future: is it time to change the DSM approach to psychiatric disorders? The case of depression. Psychiatry 2007;70:85-99
90. Weissbecker I, Floyd A, Dedert E, et al. Childhood trauma and diurnal cortisol disruption in fibromyalgia syndrome. Psychoneuroendocrinology 2006;31:312-24
91. Heim C, Plotsky PM, Nemeroff CB. Importance of studying the contributions of early adverse experience to neurobiological findings in depression. Neuropsychopharmacology 2004; 29:641-8
92. Altindag O, Celik H. Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. Redox Rep 2006; 11:131-5
93. Sarandol A, Sarandol E, Eker SS, et al. Major depressive disorder is accompanied with oxidative stress: short-term anti-depressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 2007;22:67-73
94. Maes M, De Vos N, Pioli R, et al. Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord 2000;58:241-6
95. Torpy DJ, Papanicolaou DA, Lotsikas AJ, et al. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia. Arthritis Rheum 2000;43:872-80
96. Wallace DJ, Linker-Israeli M, Hallegua D, et al. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 2001;40:743-9
97. Bendtsen L, Norregaard J, Jensen R, et al. Evidence of qualitatively altered nociception in patients with fibromyalgia. Arthritis Rheum 1997;40:98-102
98. Bennett M. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 1999;74:385-98
99. Bennett R, Doubell TP, Mannion RJ, et al. The dorsal horn: state dependent sensory processing, plasticity and the generation. In: Textbook of Pain. London: Churchill Livingstone, 2000
100. Mountz JM, Bradley LA, Modell JG, et al. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995;38:926-38
101. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37:1593-601
102. Laske C, Stransky E, Eschweiler GW, et al. Increased BDNF serum concentration in fibrornyalgia with or without depression or antidepressants. J Psychiatr Res 2007;41:600-5
103. Zelman DC, Howland EW, Nichols SN, et al. The effects of induced mood on laboratory pain. Pain 1991;46:105-11
104. Lautenbacher S, Roscher S, Strian D, et al. Pain perception in depression: relationships to symptomatology and naloxone-sensitive mechanisms. Psychosom Med 1994;56:345-52
105. Bar KJ, Brehm S, Boettger MK, et al. Pain perception in major depression depends on pain modality. Pain 2005; 117:97-103
106. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum 2008;37:339-52Epub 2008 Jan 14
107. Demyttenaere K, Bruffaerts R, Lee S, et al. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. Pain 2007;129:332-42
108. Ahles TA, Yunus MB, Masi AT. Is chronic pain a variant of depressive disease? The case of primary fibromyalgia syndrome. Pain 1987;29:105-11
109. Sundgren PC, Petrou M, Harris RE, et al. Diffusion-weighted and diffusion tensor imaging in fibromyalgia patients: a prospective study of whole brain diffusivity, apparent diffusion coefficient, and fraction anisotropy in different regions of the brain and correlation with symptom severity. Acad Radiol 2007;14:839-46
110. Giesecke T, Gracely RH, Williams DA, et al. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum 2005;52:1577-84
111. van Koulil S, Effting M, Kraaimaat FW, et al. Cognitive-behavioural therapies and exercise programmes for patients with fibromyalgia: state of the art and future directions. Ann Rheumatic Dis 2007;66:571-81
112. King SJ, Wessel J, Bhambhani Y, et al. Predictors of success of intervention programs for persons with fibromyalgia. J Rheumatol 2002;29:1034-40
113. Turk DC, Okifuji A, Sinclair JD, et al. Differential responses by psychosocial subgroups of fibromyalgia syndrome patients to an interdisciplinary treatment. Arthritis Care Res 1998; 11:397-404
114. Dwight MM, Arnold LM, O'Brien H, et al. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998;39:14-17
115. Pae CU, Masand PS, Krulewicz S, et al. Predictor of treatment response: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. Unpublished Data
116. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994;23:255-9
117. Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995;61:445-9
118. Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum 1994;37:32-40
119. Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-9
120. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15
121. Arnold LM, Keck PE, Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000;41:104-13
122. Arnold LM, Hess EV, Hudson JI, et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002;112:191-7
123. O'Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000;15:659-66
124. Patkar AA, Masand PS, Krulewicz S, et al. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med 2007;120:448-54
125. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram. in patients with fibromyalgia - a randomized, double-blind, placebo-controlled study. Eur J Pain 2000;4:27-35
126. Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19(Suppl 1):S27-35
127. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975-85
128. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50:2974-84
129. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44
130. Perahia DG, Pritchett YL, Desaiah D, et al. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol 2006;21:311-17
131. Patkar AA, Bilal L, Masand PS. Management of fibromyalgia. Curr Psychiatry Rep 2003;5:218-24
132. Arnold LM, Pritchett YL, D'Souza DN, et al. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health 2007;16:1145-56
133. Spielmans GI. Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis. Psychother Psychosom 2008;77:12-16
134. Khan A, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 2007;27: 481-92
135. Pigott TA, Prakash A, Arnold LM, et al. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin 2007;23:1303-18
136. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007;23:401-16
137. United States Food and Drug Administration. FDA Approves First Drug for Treating Fibromyalgia. 2007 cited; Available from: http://www.fda.gov/ bbs/topics/NEWS/2007/NEW01656.html
138. Weiner DK. Office management of chronic pain in the elderly. Am J Med 2007;120:306-15
139. Robinson RL, Birnbaum HG, Morley MA, et al. Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently. J Rheumatol 2004;31:1621-9
140. Carette S, McCain GA, Bell DA, et al. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum 1986;29:655-9
141. Caruso I, Sarzi Puttini PC, Boccassini L, et al. Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1987;15:154-9
142. Carette S, Oakson G, Guimont C, et al. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 1995;38:1211-17
143. Bibolotti E, Borghi C, Pasculli E, et al. The management of fibrositis: A double-blind comparison of maprotiline (Ludiomil), chlorimipramine, and placebo. J Clin Trials 1986;23:269-80
144. Simms RW, Felson DT, Goldenberg DL. Development of preliminary criteria for response to treatment in fibromyalgia syndrome. J Rheumatol 1991;18:1558-63